Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis

Journal of the National Cancer Institute

Volumn 89, Issue 14, 1997, Pages 1036-1044

  Gomez Manzano, Candelaria ^a   Fueyo, Juan ^a   Kyritsis, Athanassios P ^a   McDonnell, Timothy J ^a   Steck, Peter A ^a   Levin, Victor A ^a   Yung, W K Alfred ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MUTANT PROTEIN; PROTEIN BAX; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE TRANSFER; GLIOMA CELL; HUMAN; HUMAN CELL;

EID: 0030838479     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.14.1036     Document Type: Article

References (47)

1. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-55.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
3. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70: 523-6.
4. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1 a potential mediator of p53 tumor suppression. Cell 1993;75: 817-25.
5. 1 cyclin-dependent kinases. Cell 1993;75:805-16.
6. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A 1995;92:8493-7.
7. Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 1992;71: 505-14.
8. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
9. Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB, et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci U S A 1995;92:7834-8.
10. Haupt Y, Rowan S, Oren M. p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene 1995;10:1563-71.
11. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78:539-42.
12. Wang J, Walsh K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 1996;273:359-61.
13. Poluha W, Poluha DK, Chang B, Crosbie NE, Schonhoff CM, Kilpatrick DL, et al. The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol Cell Biol 1996;16: 1335-41.
14. Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996;10: 1945-52.
15. James CD, Carlbom E, Nordenskjold M, Collins VP, Cavenee WK. Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sci USA 1989;86:2858-62.
16. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavenee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature (London) 1992;355:846-7.
17. Anker L, Ohgaki H, Ludeke BI, Herrmann HD, Kleihues P, Westphal M. p53 protein accumulation and gene mutations in human glioma cell lines. Int J Cancer 1993;55:982-7.
18. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, et al. Adenovirus-mediated transfer of p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 1996; 56:694-9.
19. Steck PA, Gallick GE, Maxwell SA, Kloetzer WS, Arlinghaus RB, Moser RP, et al. Expression of epidermal growth factor receptor and associated glycoprotein on cultured human brain tumor cells. J Cell Biochem 1986; 32:1-10.
20. Ullrich SJ, Mercer WE, Appella E. Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. Oncogene 1992;7:1635-43.
21. Godbout R, Miyakoshi J, Dobler KD, Andison R, Matsuo K, Allalunis-Turner MJ, et al. Lack of expression of tumor-suppressor genes in human malignant glioma cell lines. Oncogene 1992;7:1879-84.
22. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, et al. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 1994;54:649-52.
23. Zhang WW, Fang X, Branch CD, Mazur W, French BA, Roth JA. Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. Biotechniques 1993;15:868-72.
24. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995;55:5151-5.
25. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, et al. Features of apoptotic cells measured by flow cytometry. Cytometry 1992;13:795-808.
26. Kitada S, Krajewski S, Miyashita T, Krajewska M, Reed JC. γ-Radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo. Oncogene 1996;12:187-92.
27. He J, Reifenberger G, Liu L, Collins PV, James CD. Analysis of glioma cell lines for amplification and overexpression of MDM2. Genes Chromosomes Cancer 1994;11:91-6.
28. Ali IU, Schweitzer JB, Ikejiri B, Saxena A, Robertson JT, Oldfield EH. Heterogeneity of subcellular localization of p53 protein in human glioblastomas. Cancer Res 1994;54:1-5.
29. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
30. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345-7.
31. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A 1992;89:4495-9.
32. Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW, et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A 1990;87:6166-70.
33. Van Meir EG, Roemer K, Diserens AC, Kikuchi T, Rempel SA, Haas M, et al. Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells. Proc Natl Acad Sci U S A 1995;92:1008-12.
34. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 1990;62:671-80.
35. 2/M by p53. Oncogene 1995;10:109-15.
36. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, et al. A p53-dependent mouse spindle checkpoint. Science 1995;267: 1353-6.
37. Vikhanskaya F, Erba E, D'Incalci M, Broggini M. Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res 1994;22:1012-7.
38. 1 cyclin-dependent kinases. Nature 1995;376:88-91.
39. 2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene 1995;10:2263-70.
40. Pandey S, Wang E. Cells en route to apoptosis are characterized by the upregulation of c-fos, c-myc, c-jun, cdc2, and RB phosphorylation, resembling events of early cell-cycle traverse. J Cell Biochem 1995;58:135-50.
41. Haas-Kogan DA, Kogan SC, Levi D, Dazin P, T'Ang A, Fung YK, et al. Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 1995; 14:461-72.
42. WAF1/Cip1 in human brain tumors. Oncogene 1995;11:2021-8.
43. Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D, Deisseroth AB. High levels of constitutive WAF-1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res 1995; 1:1051-7.
44. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
45. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362: 847-9.
46. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996;56:556-62.
47. Stone S, Dayananth P, Kamb A. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res 1996;56:3199-202.